Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Saudi Arabia to Showcase Ambitious Biotech Agenda at BIO 2025
-
Prime Announces Selection of Ausenco to Lead PEA Study Work
-
MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan
-
Brixton Metals Commences Drilling at its Thorn Copper-Gold Project
-
Abercrombie & Fitch Co. Reports First Quarter Fiscal 2025 Results
-
PyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica Samples
-
Edible Garden Estimates Over 25% Year-Over-Year Increase in Preliminary Herb Sales During Easter Holiday Period
-
Nykredit Realkredit A/S publishes supplement no 1 to Base Prospectus dated 8 May 2025 - Nykredit Realkredit A/S
-
On the extension of the term of operation of UAB „Atsinaujinančios energetikos investicijos“
-
Tokenize! Global Wraps Up Bitcoin Week with Leading Investor Summit
-
Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain for Expanded Commercial Production
-
Form 8.3 - [Alpha Group International PLC]
-
Ress Life Investments A/S announces capital increase
-
Harfang Intersects 4.5 g/t Au Over 15.6 m and Delineates New High-Grade Mineralized Shoot at Sky Lake, Ontario
-
ROCKWOOL A/S – transactions in connection with share buy-back programme
-
Orion Group Holdings Announces Dual Listing
-
Live Coin Watch Exclusive: Bitcoin Solaris Announces Phase 5 Presale Ahead of Nova App Mining Launch
-
Churchill Very Pleased to Report High Grade Antimony >10%Sb, and Gold >10g/t Au at Black Raven Past-Producers, NL
-
BPGbio Presents Advances in Spatial Omics Technology and Targeted Protein Degradation Insights at ASMS 2025
-
Major Drilling to Release Results for its Fourth Quarter and Fiscal 2025 on June 11, 2025
-
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
-
Sono-Tek Reports Strong Fiscal Year 2025 Financial Results
-
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
-
BioStem Announces Notice of Allowance for Three New U.S. Patent Applications
-
Leading Global Manufacturer Requests HPQ’s First Batch of Fumed Silica for Evaluation
-
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
-
Worksport Secures ISO 9001 Certification at U.S. Factory, Unlocking Revenue & OEM Growth Pathways
-
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
-
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration
-
DAVIDsTEA Delivers Strong Turnaround in Fourth Quarter and Full Year Fiscal 2024 Results
-
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
-
Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors
-
Worksport Secures ISO 9001 Certification at U.S. Factory, Unlocking Revenue & OEM Growth Pathways
-
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
-
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
-
Newton Golf Company (NASDAQ: NWTG) Regains Compliance with Nasdaq Listing Requirements
-
Contentstack Appoints Josette Leslie as Chief Financial Officer to Fuel Market Expansion
-
Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results
-
Triple Hair Group Strengthens Leadership Team with Appointment of Paul Sowyrda to its Board of Directors
-
NASA Visits Constellium Ravenswood to Celebrate Artemis Partnership
-
Photronics Reports Second Quarter Fiscal 2025 Results and Announces CEO Transition
-
Marketing and Sales Agency Stream Creative Featured in Google’s Annual Economic Impact Report
-
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscula
-
Verve Therapeutics to Participate in Upcoming Investor Conferences
-
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
-
OTC Markets Group Welcomes Magna Mining Inc. to OTCQX
-
Balchem Corporation to Present at the Wells Fargo Industrials and Materials Conference on June 11, 2025
-
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
-
Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors
-
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split

